A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.
The C-MOPP regimen, consisting cyclophosphamide, vincristine, prednisolone and procarbazine, has been used for treatment of non-Hodgkin lymphoma; however, there are few reports of this therapy against aggressive lymphoma. We performed a retrospective analysis of previously treated 89 patients who had received C-MOPP therapy from 1999 to 2013 at our institution. Median age was 67 (range, 22-81) years. Twenty-eight patients obtained CR, 5 obtained PR, and overall response rate was 37% (33/89). The estimated 1-year overall survival and progression-free survival rates were 61 and 33%, respectively. Major grade > 2 toxicities were leucopenia (55%) and neutropenia (52%). Efficacy and toxicity were in line with other recent studies involving new agents, given that the subjects mainly consisted of elderly outpatients. These data provide a rationale for the use of C-MOPP as a current control treatment arm when the response to new cancer therapy agents is evaluated.
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Ryoko
R
Fukushima
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Yukio
Y
Kobayashi
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Suguru
S
Fukuhara
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Ken'ichi
K
Miyamoto
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Wataru
W
Munakata
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Dai
D
Maruyama
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Sung-Won
SW
Kim
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Takashi
T
Watanabe
b Department of Pathology and Clinical Laboratory , National Cancer Center Hospital , Tokyo , Japan.
Hirokazu
H
Taniguchi
b Department of Pathology and Clinical Laboratory , National Cancer Center Hospital , Tokyo , Japan.
Akiko
A
Maeshima
a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Kensei
K
Tobinai
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
D011344:Procarbazine; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone
Non-Hodgkin lymphoma; Palliative chemotherapy; Refractory; Relapsed; Salvage therapy